Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
New Data for Fantom in Heart Attack Patients to be Presented at the TCT 2018 Conference

2018-08-16 globenewswire
SAN DIEGO, Aug. 15, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, will present new data on the use of the Fantom bioresorbable scaffold in patients experiencing heart attacks during the upcoming Transcatheter Cardiovascular Therapeutics (“TCT”) Conference, being held September 21st through 25th in San Diego, California, USA.
RVA RVA RVALL

0
REVA Medical Reports Second Quarter 2018 Financial Results

2018-08-07 globenewswire
SAN DIEGO, Aug. 07, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular medical applications, today provided a business update and reported financial results for the second quarter ended June 30, 2018.
RVA RVA RVALL

0
REVA to Hold Second Quarter 2018 Financial Results Call

2018-07-31 globenewswire
SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) has scheduled a conference call to review its second quarter 2018 financial results and provide a business update.
RVA RVA RVALL

0
UPDATE: REVA Enters Peripheral Artery Disease Space With First-Ever CE Mark of a Bioresorbable Scaffold for Below the Knee Therapy

2018-07-26 globenewswire
SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, today announced that its MOTIV™ bioresorbable scaffold is the first drug-eluting bioresorbable scaffold to receive CE Mark approval for treatment of below the knee peripheral artery disease. Late last year, REVA announced its plans to expand use of its bioresorbable scaffold technology in peripheral artery disease.
RVA RVA RVALL

0
REVA Enters Peripheral Artery Disease Space With First-Ever CE Mark of a Bioresorbale Scaffold for Below the Knee Therapy

2018-07-25 globenewswire
SAN DIEGO, July 25, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, today announced that its MOTIV™ bioresorbable scaffold is the first drug-eluting bioresorbable scaffold to receive CE Mark approval for treatment of below the knee peripheral artery disease. Late last year, REVA announced its plans to expand use of its bioresorbable scaffold technology in peripheral artery disease.
RVA RVA RVALL

0
Reva Expands Commercial Access to Fantom With New Distribution Partnership in Italy

2018-07-15 globenewswire
SAN DIEGO, July 15, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, is expanding commercial access to the Fantom® Bioresorbable Scaffold with a new distribution partnership in Italy. REVA will work with Bio Vascular Group S.R.L. (“Bio Vascular”) on commercial activities nationwide. Following this agreement, the first commercial implant procedure in Italy was conducted by Dr.
RVA RVA RVALL

6
Rounds Report: Solid Rallied Aggressively Due To The Clinical Hold Removal For IGNITE DMD

2018-06-21 seekingalpha
The overall bioscience market moved significantly northbound. Many firms under our coverage continued to procure increasing profits for shareholders.
SLDB RVA RVA RVALL IBB XBI RGNX

0
REVA Extends Technological Lead in Bioresorbable Scaffolds With CE Mark Approval of the Full Fantom® Encore Product Line

2018-06-18 globenewswire
SAN DIEGO, June 18, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, today announced it has received CE Mark approval for its full Fantom® Encore product line. This covers Fantom Encore in the 3.0 and 3.5 mm diameters, expanding the approved product line beyond the 2.5 mm diameter scaffold, which has a market-leading strut profile of 95 microns.
RVA RVA RVALL

0
Fantom’s Positive Two-Year Results Show Sustained Safety and Efficacy

2018-05-23 globenewswire
SAN DIEGO, May 23, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, reported sustained safety and efficacy of the Fantom® bioresorbable scaffold (“BRS”) through two years based on data from the FANTOM II trial presented today at the EuroPCR conference in Paris, France. The Company also revealed the strut profiles of its Fantom Encore product line, which will have strut profiles of 95 microns for the 2.
RVA RVA RVALL

0
REVA Announces First Implants of the Fantom Bioresorbable Scaffold in Turkey

2018-05-16 globenewswire
SAN DIEGO, May 15, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced today launch of the Fantom bioresorbable scaffold in Turkey with implants conducted during the first week of introduction at three separate hospitals. The procedures were conducted in Istanbul and Antalya by Prof. Bilal Boztosun, Chief of Cardiology at the Mega Medipol University Hospital, Prof.
RVA RVA RVALL

0
REVA to Hold Annual General Meeting of Stockholders

2018-05-09 globenewswire
SAN DIEGO, May 09, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) will hold its 2018 Annual General Meeting of Stockholders (the “AGM”) on Wednesday, May 16, 2018 at 4:00 p.m. US PDT (which is Thursday, 17 May 2018 at 9:00 a.m. AEST). The meeting will be held at the offices of DLA Piper LLP (US), 4365 Executive Drive, Suite 1100, San Diego, California 92121.
RVA RVA RVALL

0
REVA Medical Reports First Quarter 2018 Financial Results

2018-05-09 globenewswire
SAN DIEGO, May 09, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular medical applications, today reported financial results for the first quarter ended March 31, 2018.
RVA RVA RVALL

0
REVA to Hold First Quarter 2018 Financial Results Call

2018-05-01 globenewswire
SAN DIEGO, May 01, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) has scheduled a conference call to review its first quarter 2018 financial results and provide a business update.
RVA RVA RVALL

0
REVA to Present Full Two-Year FANTOM II Data at EuroPCR

2018-04-16 globenewswire
SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced that it will be presenting two-year data from its FANTOM II clinical study at the EuroPCR Conference to be held in Paris, France at the Palais des Congres from May 22, 2018 through May 25, 2018. Data will be presented in a symposium to be held on May 23, 2018 from 12:15 p.
RVA RVA RVALL

Related Articles

RNVA: Rennova Health Analysis and Research Report

2018-08-18 - Asif

Business overview Rennova Health, Inc. (together with its subsidiaries, “Rennova”, “we” or the “Company”) is a provider of an expanding group of health care services for healthcare providers, patients and individuals. Beginning in 2018, the Company intends to focus on and operate two synergistic divisions: 1) Clinical diagnostics through its clinical laboratories; and 2) Hospital operations through its Big South Fork Medical Center, which opened on August 8, 2017, and a hospital in Jamestown Tennessee, including a doctor’s practice, the assets of which the company expect to acquire in the second quarter of 2018, pursuant to the terms of a definitive asset purchase agreement that the company entered into on January 31, 2018, as more fully discussed below. The company believe that its approach will produce a more sustainable business model and the capture of multiple revenue streams from medical providers, patients and hospital services. Management determined that because Big So...

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...